How Novartis Pharma AG is targeting the last untreated segment in malaria care
Discover how Novartis Pharma AG is targeting neonatal malaria with Coartem Baby and what WHO prequalification means for global access.
Pharma & Biotech
Pharma & Biotech
Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients
Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.
Pharma & Biotech
Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.
Pharma & Biotech
Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.